[go: up one dir, main page]

MX2007015935A - Agentes y metodos basados en el uso del dominio eda de la fibronectina. - Google Patents

Agentes y metodos basados en el uso del dominio eda de la fibronectina.

Info

Publication number
MX2007015935A
MX2007015935A MX2007015935A MX2007015935A MX2007015935A MX 2007015935 A MX2007015935 A MX 2007015935A MX 2007015935 A MX2007015935 A MX 2007015935A MX 2007015935 A MX2007015935 A MX 2007015935A MX 2007015935 A MX2007015935 A MX 2007015935A
Authority
MX
Mexico
Prior art keywords
eda domain
fibronectine
agents
methods based
fragment
Prior art date
Application number
MX2007015935A
Other languages
English (en)
Inventor
Valtuena Jesus Prieto
Sagastibelza Juan Jose Lasarte
Claude Leclerc
Ayala Marta Gorraiz
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of MX2007015935A publication Critical patent/MX2007015935A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere al empleo de un polipeptido que comprende una secuencia correspondiente al dominio EDA de la fibronectina, un fragmento de dicho dominio EDA capaz de unirse a TLER4, o una variante de dicho dominio EDA o fragmento que es capaz de unirse a TLR4 y presenta una homologia mayor del 70% con cualquier forma o fragmento natural del dominio EDA, en la elaboracion de un agente inmunoestimulador. La prsente invencion se refiere tambien a los metodos de produccion y las aplicaciones del citado agente.
MX2007015935A 2005-06-13 2006-06-13 Agentes y metodos basados en el uso del dominio eda de la fibronectina. MX2007015935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200501412A ES2291071B1 (es) 2005-06-13 2005-06-13 Agentes y metodos basados en el uso del dominio eda de la fibronectina.
PCT/ES2006/000343 WO2006134190A2 (es) 2005-06-13 2006-06-13 Agentes y métodos basados en el uso del dominio eda de la fibronectina

Publications (1)

Publication Number Publication Date
MX2007015935A true MX2007015935A (es) 2008-04-21

Family

ID=37532656

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015935A MX2007015935A (es) 2005-06-13 2006-06-13 Agentes y metodos basados en el uso del dominio eda de la fibronectina.

Country Status (14)

Country Link
US (2) US9155783B2 (es)
EP (1) EP1913954B8 (es)
JP (1) JP4970435B2 (es)
CN (1) CN101287487B (es)
AU (1) AU2006259041B2 (es)
BR (1) BRPI0611782A2 (es)
CA (1) CA2612151C (es)
DK (1) DK1913954T3 (es)
ES (2) ES2291071B1 (es)
MX (1) MX2007015935A (es)
PL (1) PL1913954T3 (es)
PT (1) PT1913954E (es)
RU (1) RU2430738C2 (es)
WO (1) WO2006134190A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745603A1 (en) 2008-12-03 2010-06-10 Proyecto De Biomedicina Cima, S.L. Use of phenol soluble modulins for the development of vaccines
US20120237535A1 (en) * 2009-09-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Therapeutic Compositions For The Treatment of HPV-Induced Diseases
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
WO2011101332A1 (en) * 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
AU2011323205A1 (en) * 2010-11-04 2013-06-27 The Board Of Regents Of The University Of Oklahoma Peptide compositions that downregulateTLR-4 signaling pathway and methods of producing and using same
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
JP6283347B2 (ja) * 2013-03-06 2018-02-21 タカラバイオ株式会社 成熟樹状細胞集団の製造方法
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
RS65430B1 (sr) 2016-03-16 2024-05-31 Amal Therapeutics Sa Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2018162450A1 (en) * 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CR20230155A (es) 2020-09-14 2023-06-27 Boehringer Ingelheim Int Vacuna heteróloga de estímulo primario
US20220111028A1 (en) 2020-10-14 2022-04-14 Boehringer Ingelheim International Gmbh Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist
MX2024011238A (es) 2022-03-16 2024-09-19 Boehringer Ingelheim Int Antigenos tumorales, compuestos que comprenden los antigenos tumorales kras, tpx2 o aurka y usos de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108898A (en) * 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
AU5488900A (en) * 1999-06-14 2001-01-02 General Hospital Corporation, The Modulators of fibrosis
ATE438409T1 (de) * 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
JP2005523887A (ja) * 2002-01-03 2005-08-11 シエーリング アクチエンゲゼルシャフト 腫瘍の新しい診断および治療方法
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
FR2855758B1 (fr) * 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
AU2005280528B2 (en) * 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin

Also Published As

Publication number Publication date
EP1913954A4 (en) 2011-01-12
US20090220532A1 (en) 2009-09-03
RU2430738C2 (ru) 2011-10-10
AU2006259041A1 (en) 2006-12-21
CA2612151A1 (en) 2006-12-21
JP4970435B2 (ja) 2012-07-04
WO2006134190A3 (es) 2007-02-22
PL1913954T3 (pl) 2013-01-31
JP2008543301A (ja) 2008-12-04
CN101287487B (zh) 2013-02-06
EP1913954B1 (en) 2012-08-08
PT1913954E (pt) 2012-11-19
US9155783B2 (en) 2015-10-13
CN101287487A (zh) 2008-10-15
BRPI0611782A2 (pt) 2010-09-28
CA2612151C (en) 2015-01-13
ES2291071A1 (es) 2008-02-16
AU2006259041B2 (en) 2012-02-02
ES2291071B1 (es) 2009-03-16
WO2006134190A2 (es) 2006-12-21
EP1913954B8 (en) 2012-09-19
RU2008100242A (ru) 2009-07-20
US20160215039A1 (en) 2016-07-28
EP1913954A2 (en) 2008-04-23
WO2006134190A8 (es) 2008-01-31
DK1913954T3 (da) 2012-11-26
ES2392659T3 (es) 2012-12-12

Similar Documents

Publication Publication Date Title
MX2007015935A (es) Agentes y metodos basados en el uso del dominio eda de la fibronectina.
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
PT1284998E (pt) Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
CR8991A (es) Sustituto funcional del azucar
PE20070499A1 (es) Composicion inmunogenica
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
AR059330A1 (es) Composiciones acondicionadoras del cabello
GT200200133A (es) Formulaciones de latex libres de aceleradores, metodos para hacer dichas formulaciones y articulos hechos de los mismos
DE602004019780D1 (de) Eugnis
UY29954A1 (es) Composicion edulcorante de alta intensidad con un agente antiinflamatorio y composiciones endulzadas con ella
CY1113770T1 (el) Κυκλικα αντι-μικροβιακα πεπτιδια
AR068212A1 (es) Composicion acondicionadora de telas
ATE451100T1 (de) Pharmazeutische wundheilungszusammensetzungen in form einer crome auf basis von aminosäuren und natriumhyaluronat
AR047651A1 (es) Composicion alimenticia con fibras
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
UY3385Q (es) Cepillo dental
PA8571901A1 (es) Nueva composicion farmaceutica
PL1848918T3 (pl) Urządzenie oświetleniowe
BRPI0607993A2 (pt) artigo de lã lavável compreendendo lã que foi tratada para remover pelo menos uma porção de suas escamas e método para produzir um artigo "stretch" de lã lavável e dimensionalmente estável
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
UY30198A1 (es) Dominios kunitz quiméricos y su uso
DK1968033T3 (da) Visningsindretning med holdeelement
DE602005025202D1 (de) Subtilasevarianten mit veränderter immunogenität
ATE399532T1 (de) Medizinische seife
AR043707A1 (es) Cpmposiciones para el tratamiento de telas y componentes para ello

Legal Events

Date Code Title Description
FG Grant or registration